Home > Newsroom
 
May 19, 2010
RANBAXY LAUNCHES ATORVASTATIN CHOLESTEROL-REDUCING MEDICATION INTO THE CANADIAN HEALTHCARE SYSTEM
 
Jul 29, 2009
RANBAXY GAINS APPROVAL TO MARKET RANTM-ROPINIROLE TABLETS IN CANADA
 
Jul 21, 2009
RANBAXY RECEIVES FINAL APPROVAL TO MANUFACTURE AND MARKET RANTM-SIMVASTATIN TABLETS IN CANADA
 
Jul 20, 2009
RANBAXY RECEIVES FINAL APPROVAL TO MANUFACTURE AND MARKET RANTM-AMLODIPINE TABLETS IN CANADA
 
Nov 21, 2007
RANBAXY LAUNCHES RANTM-TAMSULOSIN HYDROCHLORIDE CAPSULES IN CANADA
 
Oct 22, 2007
RANBAXY RECEIVES APPROVAL TO MARKET RANTM-LISINOPRIL IN CANADA
 
Sep 13, 2007
CANADIAN FEDERAL COURT FAVOURS RANBAXY - DISMISSES PFIZER'S APPLICATION ON ATORVASTATIN PATENT CA 2,220,455
 
May 21, 2007
RANBAXY RECEIVES APPROVAL TO MARKET RANTM-PRAVASTATIN IN CANADA
 
Apr 11, 2007
RANBAXY RECEIVES APPROVAL TO MARKET CEFPROZIL TABLETS AND CEFPROZIL POWDER FOR ORAL SUSPENSION IN CANADA
 
Feb 07, 2007
RANBAXY ANNOUNCES GLOBAL ENTRY INTO BIOSIMILARS WITH ZENOTECH TARGETS EU MARKETS FIRST
 


 

For further information please contact:


Ramesh L. Adige

President - Corporate Affairs
and Global Corporate Communications
Ranbaxy Laboratories Ltd.
Plot 90, Sector 32, Gurgaon
Haryana 122001, India
Tel: +91-124-5135000
e-mail: ramesh.adige@ranbaxy.com

or

Raghu Kochar
Director-Corporate Communications
Ranbaxy Laboratories Ltd
Plot 90, Sector 32, Gurgaon
Haryana 122001, India
Tel: +91-124-5135141
Mobile: 9811617256
e-mail: raghu.kochar@ranbaxy.com

or

Krishnan Ramalingam
General Manager - Corporate Communications
Ranbaxy Laboratories Ltd.
Plot 90, Sector 32, Gurgaon
Haryana 122001, India
Tel: +91-124-5135143
Mobile: 9810042540
e-mail: krishnan.ramalingam@ranbaxy.com